Mu et al. found that the combination of AI and image signatures based on 18F-fluorodeoxyglucose (FDG) PET/CT before ICI initiation can predict PD-L1 expression and identify patients with non-small cell lung cancer (NSCLC) who may have a favorable response to treatment [21]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.